Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06952803

PHASE3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).

Official title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

700

Start Date

2025-08-06

Completion Date

2036-04-30

Last Updated

2026-10-14

Healthy Volunteers

Conditions

Prostate Cancer

Interventions

DRUG

Saruparib

Saruparib will be administered orally.

DRUG

Placebo

Matching placebo to saruparib will be administered orally.

DRUG

Abiraterone + Prednisolone/Prednisone

Abiraterone will be administered orally in combination with prednisone/prednisolone.

DRUG

Androgen Deprivation Therapy (ADT)

Standard of care ADT will be administered.

Inclusion Criteria: * Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical recurrence (BCR) following radical prostatectomy. * Provision of a formalin fixed and paraffin embedded (FFPE) tumour tissue sample. * Confirmed BRCA1 or BRCA2 mutation status by central tumour tissue is required for enrolment. * Participants required to have a computed tomography (CT) or magnetic resonance imaging (MRI) and a bone scan following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0). * Participants required to have a prostate-specific membrane antigen-positron emission tomography (PSMA-PET) following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomization. * Minimum life expectancy of 12 months. * Adequate organ and bone marrow function as described in study protocol. * All participants will have received either primary or salvage RT. Participants must be eligible for randomisation within 10 months of initial diagnosis (de novo or BCR). Radiotherapy administered to the prostate (± pelvis) either in the primary or salvage setting must be delivered with curative intent. Use of metastases-directed therapy, as part of the RT radiation plan, is permitted as localised RT treatment for a metastatic lesion(s) outside the pelvis. * All participants will have received a planned regimen of ADT with a gonadotropin releasing hormone (GnRH) analogue. * Participants must not father children or donate sperm from signing informed consent form (ICF), during the study intervention and for 6 months after the last dose of study intervention. * Participants must use a condom (with spermicide - where permitted) from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners. Exclusion Criteria: * Participants with a history of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) or with features suggestive of MDS/AML. * Participants with any known predisposition to bleeding \[e.g., active peptic ulceration, recent (within 6 months) hemorrhagic stroke, proliferative diabetic retinopathy\]. * Any history of persisting (\> 2 weeks) severe cytopenia due to any cause. * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib and/or abiraterone. * History of another primary malignancy, with exceptions. * Persistent toxicities \[Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2\] caused by previous anticancer therapy. * Cardiac criteria, including history of arrhythmia and cardiovascular disease. * Evidence of active and uncontrolled hepatitis B and/or hepatitis C. * Evidence of active and uncontrolled human immunodeficiency virus (HIV) infection. * Active tuberculosis infection. * Any prior chemotherapy (i.e., docetaxel) or immunotherapy; any prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor. * Prior treatment within 14 days with blood product support or growth factor support. * Concomitant use of strong inducers and inhibitors of CYP3A4 (applies to saruparib and abiraterone) or herbal supplements within 21 days or at least 5 half-lives (whichever is longer), of randomization. * Concomitant use of drugs that are known to prolong QT and have a known risk of Torsades de Pointes (TdP). * Participants with a known hypersensitivity to saruparib or any excipients of these products.

Locations (346)

Research Site

Phoenix, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

La Jolla, California, United States

Research Site

La Jolla, California, United States

Research Site

Los Angeles, California, United States

Research Site

San Diego, California, United States

Research Site

San Luis Obispo, California, United States

Research Site

Lakewood, Colorado, United States

Research Site

Hialeah, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Tallahassee, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Newnan, Georgia, United States

Research Site

Chicago, Illinois, United States

Research Site

Chicago Ridge, Illinois, United States

Research Site

Lake Barrington, Illinois, United States

Research Site

Greenwood, Indiana, United States

Research Site

Jeffersonville, Indiana, United States

Research Site

Bethesda, Maryland, United States

Research Site

Towson, Maryland, United States

Research Site

Plymouth, Massachusetts, United States

Research Site

Rochester, Minnesota, United States

Research Site

Hackensack, New Jersey, United States

Research Site

Voorhees Township, New Jersey, United States

Research Site

Albany, New York, United States

Research Site

New York, New York, United States

Research Site

Syracuse, New York, United States

Research Site

Columbus, Ohio, United States

Research Site

Springfield, Oregon, United States

Research Site

Hershey, Pennsylvania, United States

Research Site

Lancaster, Pennsylvania, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Providence, Rhode Island, United States

Research Site

Myrtle Beach, South Carolina, United States

Research Site

Nashville, Tennessee, United States

Research Site

Austin, Texas, United States

Research Site

Austin, Texas, United States

Research Site

Houston, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Spring, Texas, United States

Research Site

Salt Lake City, Utah, United States

Research Site

Norfolk, Virginia, United States

Research Site

Roanoke, Virginia, United States

Research Site

Virginia Beach, Virginia, United States

Research Site

Seattle, Washington, United States

Research Site

CABA, Argentina

Research Site

CABA, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Córdoba, Argentina

Research Site

Córdoba, Argentina

Research Site

Cuidad Autónoma de Buenos Aire, Argentina

Research Site

La Plata, Argentina

Research Site

Pergamino, Argentina

Research Site

Rosario, Argentina

Research Site

San Miguel de Tucumán, Argentina

Research Site

Viedma, Argentina

Research Site

Kingswood, Australia

Research Site

Murdoch, Australia

Research Site

Orange, Australia

Research Site

South Brisbane, Australia

Research Site

St Leonards, Australia

Research Site

Waratah, Australia

Research Site

Woolloongabba, Australia

Research Site

Graz, Austria

Research Site

Innsbruck, Austria

Research Site

Linz, Austria

Research Site

Vienna, Austria

Research Site

Vienna, Austria

Research Site

Brussels, Belgium

Research Site

Brussels, Belgium

Research Site

Ghent, Belgium

Research Site

Jette, Belgium

Research Site

Kortrijk, Belgium

Research Site

Leuven, Belgium

Research Site

Libramont-Chevigny, Belgium

Research Site

Roeselare, Belgium

Research Site

Wilrijk, Belgium

Research Site

Barretos, Brazil

Research Site

Cachoeiro de Itapemirim, Brazil

Research Site

Curitiba, Brazil

Research Site

Curitiba, Brazil

Research Site

Jaú, Brazil

Research Site

Londrina, Brazil

Research Site

Pelotas, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Recife, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Salvador, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Calgary, Alberta, Canada

Research Site

Abbotsford British Columbia, British Columbia, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

Barrie, Ontario, Canada

Research Site

Brampton, Ontario, Canada

Research Site

London, Ontario, Canada

And 246 more locations on ClinicalTrials.gov

Clinical Research Directory

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (346)